April 22, 2016—The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency community to promote World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PI.
April 17, 2015–The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia (WFH) that seeks to raise awareness of people living with inherited bleeding disorders.
The Food and Drug Administration (FDA) released its final guidance (Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry) for industry on reducing the risk of HIV transmission through blood and blood products today.
On October 11, 2012, the German Federal Ministry of Health (BMG) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the treatment of haemophilia patients through the production of a Health Technology Assessment (HTA) Rapid Report.
[Blood Products Advisory Committee Meeting on December 2, 2014]
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies, collectively referred to as plasma protein therapies. Plasma protein therapies are used in the treatment of a number of rare diseases.
During the October, 21 2016, Source Board of Directors meeting, the Board agreed to remove the voluntary deferral for 60 days of donors returning from Ebola virus disease affected areas in the previous 60 days. The deferral was originally implemented on or about October 13, 2014.
Dear PPTA Stakeholders:
I would like to provide a status report on implementation of PPTA’s European Data Program.
As you know, PPTA launched the program in November 2013 starting with the reporting of Recombinant Factor VIII data. We committed as well to soon begin reporting data on a more complete set of plasma protein therapies. Today we are able to honor that commitment. Please click here to access the data.
The Plasma Protein Therapeutics Association (PPTA) remains deeply concerned about the proposal to ban compensated plasma donation in the Province of Ontario, Canada. The proposed legislation, Ontario Bill 178, unfairly targets compensated plasma donation on alleged bases of safety and Canada’s goal of self-sufficiency in regards to the supply of plasma-derived medicinal products.
The Plasma Protein Therapeutics Association released the following statement regarding passage of the H.R. 3590, the Patient Protection and Affordable Care Act:
"PPTA recognizes the historic achievement of President Obama and Congress in providing affordable, quality health care to millions of Americans.
Last week, the President and Congress could not come to an agreement and on March 1, 2013 sequestration, $85 billion in across the board federal spending cuts, went into effect.
